PolyPid Ltd.

NASDAQ:PYPD

Biotechnology

Healthcare
$6.56 +8.23%

+$0.39 today

Market cap
$133.25M
Beta
1.43
P/E (TTM)
-2.7
EPS (TTM)
-$1.53
52W Low $3.06High $5.21

Volume 0.30M

Average 0.09M

PYPD Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

PolyPid Ltd.NASDAQ: PYPD

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 21.92M shares rose 86.6% year over year, behind the +145.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at +132.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +86.6% toward the trailing-twelve-month pace of +145.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.92M+6.5% QoQ
Last fiscal yearDec 2025
16.35M+176.5% YoY
LTMMar 2026
18.85M+145.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.6%——
1 year+176.5%——
3-year CAGR+132.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
16.35M USD
Year-over-year change
+176.5%
4-year CAGR
+90.2%

Weighted Avg Shares vs competitors

How PYPD compares with its peers on the latest reported figures

  • PYPD's LTM Mar 2026 weighted avg shares of 18.85M shares is the 6th highest of the 7 companies compared; the peer median is 28.07M shares.
  • Its year-over-year change of +145.8% is the highest of 7, against a peer median of +24.8%.
  • Over three fiscal years its annual growth of +132.8% compares with a peer median of +22.3%.
PYPD Competitors Peer median
Weighted Avg Shares for PYPD and competitors
Company Period LTM YoY 3-year CAGR
PDSBPDS Biotechnology CorporationLTM Mar 202648.66M +29.4%+17.5%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202631.26M +0.3%+8.9%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.8%
VERUVeru Inc.LTM Mar 202617.82M +21.7%+22.3%
Peer median (excluding PYPD) 28.07M+24.8%+22.3%

Competitors are the stored peer set for PYPD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M1.72M000
Gross Profit(1.12M)(1.72M)000
Gross Margin—————
Research & Development30.42M27.99M16.15M22.81M23.81M
Selling, General & Admin12.45M10.9M6.72M5.22M9.16M
Operating Expenses42.03M37.17M22.87M28.03M32.97M
Depreciation & Amortization1.12M1.72M1.82M1.62M1.62M
EBITDA(41.48M)(36.37M)(20.26M)(25.83M)(31.86M)
EBITDA Margin—————
Operating Income(43.15M)(38.89M)(22.87M)(28.03M)(32.97M)
Operating Margin—————
Interest Income468K267K548K442K0
Interest Expense01.34M1.71M1.53M685K
Other Income / Expenses544K(540K)(929K)(951K)(1.2M)
Income Before Tax(42.6M)(39.43M)(23.8M)(28.98M)(34.16M)
Pre-Tax Margin—————
Income Tax Expense0129K69K42K5K
Net Income(40.71M)(39.53M)(23.87M)(29.02M)(34.17M)
Net Margin—————
EPS (Basic)(67.80)(61.20)(16.99)(4.91)(2.09)
EPS (Diluted)(67.80)(61.20)(16.99)(4.91)(2.09)
Weighted Avg Shares1.25M1.3M1.4M5.91M16.35M
Weighted Avg Shares (Diluted)1.25M1.3M1.4M5.91M16.35M

PolyPid Ltd.

NASDAQ:PYPD

Intrinsic Alpha fair value

Locked

Current Price

$6.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.